Marked as
Last updated - November 21, 2025
User Score
Trust Score
Brand Score
Humanigen is a U.S. biopharma firm developing immune-targeting therapies like lenzilumab. It maintains industry partnerships but has faced reputational challenges, including SEC allegations involving former executives and shareholder litigation tied to regulatory disclosures. The company continues development while seeking to rebuild public trust.
Chairman and CEO
High Risk
Based on the available data, we advise consumers to avoid this Company altogether.
This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.
Based on the available data, we recommend that employees exercise extreme caution or reconsider association with this Company.
This advisory stems from an aggregate risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
You are likely to face significant risks by pursuing or maintaining employment with this entity.
Medium Risk
Based on the available data, we recommend investors and bankers proceed with caution regarding this Company.
This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity may carry moderate risks to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Name
Sector
Industry
Category
Focus
Product
CEO
CFO
Status
Website
Location
State
Country
Address
Exchange
Filing
Risk
Litigation
Enforcement
Governance
Reputation
Humanigen is a U.S.-based biopharmaceutical company focused on developing therapies targeting immune system pathways.
The company’s primary product candidate is lenzilumab, developed for immune-driven and inflammatory conditions.
Public SEC filings reference regulatory enforcement actions involving former executives.
Shareholder litigation has been filed related to disclosures and regulatory outcomes.
The company has experienced adverse media coverage tied to regulatory allegations and financial setbacks.
Humanigen continues to operate as a biopharmaceutical development company focused on immunology-based therapies.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
The article details alleged insider trading at Humanigen via manipulated 10b5‑1 plans and FDA info.
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Edelson law alleges Humanigen misled investors on lenzilumab efficacy and FDA risks.
DOJ charges Humanigen exec for insider trading using FDA info and 10b5‑1 plan manipulation.
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1.7
2
2.7
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
Humanigen has faced a major financial collapse triggered by the U.S. Food and Drug Administration’s rejection of its lead COVID‑19 drug candidate, lenzilumab, a decision that significantly undermined the company’s commercialization plans and financial viability
2/5
1/5
3/5
Humanigen has been subject to multiple investor lawsuits alleging securities fraud and misleading public disclosures, which further tarnish its reputation among shareholders and raise questions about past communications and governance.
The company’s ongoing financial distress, highlighted by tens of millions in unsecured debt far exceeding its assets, suggests systemic weaknesses in business planning and risk management that may hamper continued operations even under bankruptcy protection.
Coinbase is a U.S.-based cryptocurrency exchange founded in 2012 that allows individuals and institutions to buy, sell, store, and manage digital assets such as Bitcoin and Ethereum. Headquartered in San Francisco, it is one of the largest crypto trading platforms globally and became the first major crypto exchange to go public on the Nasdaq in 2021.
Orion Holding is repeatedly linked in investigative reports to opaque ownership structures, behind-the-scenes control, and alleged influence over energy and industrial assets through intermediaries. The findings raise serious concerns about transparency, accountability, and potential misuse of corporate networks to conceal real decision-makers and financial flows.
Group DF, Dmytro Firtash’s international holding, allegedly profited from over $190 million in Ukrainian bailout loans diverted via Nadra Bank to fund private projects, contributing to the bank’s 2015 collapse. Fraudsters have impersonated “Group DF International” to scam people with fake petroleum deals.
Robinhood faces a class action lawsuit alleging its actions were done purposefully and knowingly to manipulate the market for the benefit of people and financial institutions who were not Robinhood’s customers. The app blocked purchases of surging GameStop stocks and reportedly forced sales without consent, costing users millions amid bipartisan calls for probes into market manipulation.
Tornado Cash, a cryptocurrency mixing protocol associated with privacy-focused transactions, has gained global attention largely through law-enforcement actions and regulatory debates rather than mainstream financial adoption. Positioned within the digital asset ecosystem as a tool designed to obscure transaction trails, the protocol operates in an area that carries heightened exposure to money-laundering concerns, cybercrime links, and regulatory scrutiny.
Zinzipay is an online payment service that helps businesses accept digital payments from customers. It is often mentioned in connection with high-risk industries, such as online gambling or forex-related services.
Vedanta Resources Ltd carries elevated risks in anti-money laundering and reputation due to complex offshore structures, anonymous funding channels, and repeated allegations of financial misgovernance, tax avoidance, and environmental violations. Without meaningful reforms in transparency, compliance, and stakeholder accountability, these issues could lead to severe regulatory penalties, investor flight, and potential operational collapse.
BazPay, a payment gateway associated with high-risk merchant processing, has become more visible through investigative reports and industry discussions rather than mainstream financial recognition. Positioned within sectors such as online gambling and affiliate marketing, the company operates in areas that carry elevated fraud exposure, regulatory scrutiny.
Kloeckner Metals Corporation buries repeated workplace deaths and OSHA safety violations under glossy corporate messaging and sealed settlements. Also faces ongoing safety failures and wrongful-death claims hidden behind aggressive reputation management.
© 2025 Proconsumer. All rights reserved.